“Learn from the lessons and don’t forget them”: Identifying transferable lessons for COVID-19 from meningitis A, yellow fever, and Ebola virus disease vaccination campaigns - Collins, Julie; Westerveld, Rosie; Nelson, Kate A; Rohan, Hana; Bower, Hilary; Lazenby, Siobhan; Ikilezi, Gloria; Bartlein, Rebecca; Bausch, Daniel G; Kennedy, David S (medRxiv, 2021)
Introduction COVID-19 vaccines are now being distributed to low- and middle-income countries (LMICs), with global urgency surrounding national vaccination plans. LMICs have significant experience implementing vaccination campaigns to respond to epidemic threats but are often hindered by chronic health system challenges. We sought to identify transferable lessons for COVID-19 vaccination from the rollout of three vaccines that targeted adult groups in Africa and South America: MenAfriVac (meningitis A); 17D (yellow fever); and rVSV-ZEBOV (Ebola virus disease).Methods We conducted a rapid literature review and 24 semi-structured interviews with technical experts who had direct implementation experience with the selected vaccines in Africa and South America. We identified barriers, enablers, and key lessons from the literature and from participants’ experiences. Interview data were analysed thematically according to seven implementation domains.Results Participants highlighted multiple components of vaccination campaigns that are instrumental for achieving high coverage. Community engagement is an essential and effective tool, requiring dedicated time, funding and workforce. Involving local health workers is a key enabler, as is collaborating with community leaders to map social groups and tailor vaccination strategies to their needs. Vaccination team recruitment and training strategies need to be enhanced to support vaccination campaigns. Although recognised as challenging, integrating vaccination campaigns with other routine health services can be highly beneficial if well planned and coordinated across health programmes and with communities.Conclusion As supplies of COVID-19 vaccines become available to LMICs, countries need to prepare to efficiently roll out the vaccine, encourage uptake among eligible groups, and respond to potential community concerns. Lessons from the implementation of these three vaccines that targeted adults in LMICs can be used to inform best practice for COVID-19 and other epidemic vaccination campaigns.KEY QUESTIONSWhat is already known?What is already known?Low- and middle-income countries (LMICs) have substantial experience conducting vaccination campaigns as a part of epidemic responses.Vaccination campaigns in LMICs are impacted by a number of systemic challenges, including poor infrastructure, limited resources, and an overstretched health workforce.Meningitis A, yellow fever and Ebola virus disease vaccines have been recently rolled out in LMICs to respond to epidemic threats. These campaigns share some of the same challenges anticipated for COVID-19 vaccination, including the focus on adult target groups.What are the new findings?What are the new findings?Extensive community engagement is crucial when targeting adults for vaccination in LMICs to shift community perceptions that vaccination is only associated with children.Working with community leaders to map social groups and plan effective vaccination strategies is vital to achieving high vaccination coverage.Recruiting local health workers who have established links to the community, can speak the local language, and can leverage existing rapport to increase vaccination uptake, is preferred over bringing in staff from other regions.Vaccination training quality is reduced as information is transmitted down to lower levels using the ‘cascade’ or ‘training-of-trainers’ model. Training for vaccination campaigns in LMICs has been further affected by COVID-19 and the move to remote learning. Where access to training is limited, a greater emphasis is placed on resource-intensive supervision to ensure the effectiveness of vaccination campaigns.What do the new findings imply?What do the new findings imply?Previous vaccination campaigns conducted during epidemics are an important source of transferable lessons that can assist countries in their COVID-19 vaccine rollouts and future epidemic preparedness.Our findings suggest that countries can strengthen vaccination campaigns during epidemics by recruiting local health workers to assist vaccination teams, by providing operational funding for pre-campaign community engagement and social mobilisation activities, and by examining the effectiveness of vaccination training and developing new models where needed.Implementing these lessons for COVID-19, however, relies on countries having sufficient vaccine supply.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by UK Aid from the Department of Health and Social Care (https://www.gov.uk/government/collections/officialdevelopment–assistance–oda–2, Grant No. IS–RRT–1015–001) via the UK Public Health Rapid Support Team Research Programme. The UK Public Health Rapid Support Team is funded by UK Aid from the Department of Health and Social Care and is jointly run by Public Health England and the London School of Hygiene &; Tropical Medicine. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the London School of Hygiene & Tropical Medicine Research Ethics Committee (ref: 24044).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe qualitative data generated through this study are not suitable for sharing beyond that contained within the manuscript in order to protect the anonymity of participants. Further information can be obtained from the corresponding author.